<DOC>
	<DOCNO>NCT01933516</DOCNO>
	<brief_summary>The purpose study evaluate safety pharmacokinetic GP2013 Japanese patient CD20 positive low tumor burden indolent B-cell NHL weekly dosing schedule .</brief_summary>
	<brief_title>GP2013 Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Patient CD20 positive low tumor burden indolent Bcell non Hodgkin 's lymphoma . Patient least one measurable lesion . Patient ECOG performance status 0 1 . Patient receive radiotherapy within last 28 day prior administration , recover previous radiotherapy . Patient receive immunotherapy , chemotherapy , antibody experimental treatment within last 28 day prior administration , recover previous therapy . Patient mAb therapy rituximab prior line therapy . Patient evidence uncontrolled , acute chronic active infection ( viral , bacterial fungal ) . Patient malignancy within 5 year prior date screening , exception adequately treat situ carcinoma cervix uterus , basal squamous cell carcinoma nonmelanomatous skin cancer . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>GP2013</keyword>
	<keyword>Japanese</keyword>
	<keyword>indolent B-cell non-Hodgkin 's lymphoma</keyword>
	<keyword>biosimilar</keyword>
	<keyword>CD20</keyword>
	<keyword>GP13-101</keyword>
</DOC>